Background
Methods/design
Study design
Participants and recruitment
Inclusion criteria | Exclusion criteria |
---|---|
Age 70 to 85 | Severe chronic condition or medication affecting cognitive and/or physical function: |
Community-dwelling | -cancer requiring treatment in the past year (except for basalioma, cancers that have been cured or carry an excellent prognosis) |
Able to walk 500 m without assistance (cane is allowed) | -severe musculoskeletal (e.g. osteoarthritis, osteoporosis with fragility fracture) disease |
-severe lung, renal or cardio-vascular disease, diabetes with insulin medication | |
Sedentary or at most moderately physically active (less than 150 min of walking/week and no regular attendance in resistance training) | -severe psychotic disorder, cognitive impairment or disease affecting cognition (e.g. Alzheimer’s disease, dementia, abnormal CERAD score), |
-serious neurological disease or disorder (e.g. Parkinson’s disease), stroke or cerebral hemorrhage with complications | |
MMSE ≥24 Informed consent to participation | Underlying diseases likely to limit lifespan and/or intervention safety. Contraindication for physical exercise or walking tests based on ACSM41 |
Other medical, psychiatric, or behavioral factor that in the judgment of the PI and study physician may interfere with study participation or the ability to follow the intervention protocol | |
Excessive and regular use of alcohol (more than 7 units per week for women and 14 for men) | |
Difficulty in communication due to severe vision or hearing problems | |
Unable or unwilling to give informed consent or accept randomization into either study group | |
Another member of the household is a participant in PASSWORD |
Description of measurements
Primary outcome
Secondary outcomes
Exploratory outcomes
Interventions
The multicomponent physical training (PT) intervention
Time, months | Programs/RM tests | Supervised resistance/balance exercise program | Supervised walking/balance exercise program | Home gymnastic program |
---|---|---|---|---|
1–2 | 6RM tests | Familiarization with equipment; RM for Leg press, Leg curl, Leg extension | 150 min of aerobic exercise/week. Outdoors activities are encouraged throughout the intervention | |
Period 1 (adoption phase) | Warm-up with balance exercises; Resistance training at 50% of 1RM, 2 × 20 reps (adoption phase) | Warm-up (walk at habitualspeed and dynamic balance exercises while walking); 10-min continuous walk with RPE 13 | Strength exercises for lower limb muscles; Postural balance exercise; Stretching exercises for major muscle groups | |
3–4 | Period 2 | Warm-up with balance exercises; Resistance training: resistance at 60% 1RM, 2 × 15 reps | Warm-up (at habitual speed, dynamic balance exercises of increasing difficulty over time while walking); 10–15 min continuous walking with RPE 13 | Strength exercises for lower limb muscles; Postural balance exercise; Stretching exercises for major muscle groups |
5–6 | Period 3 | Warm-up with balance exercises; Power training: Resistance 50% 1RM, 3 × 5 reps (fast contractions) Hypertrophy: Resistance 70% 1RM, 2 × 10 reps (resistance is increased by 1–2 kg if predefined number of reps is exceeded) | Warm-up (as in periods 3–4); 15–20-min continuous walk with RPE 13 | Strength exercises for lower limb muscles with red TheraBand CLX; Postural balance exercise; Stretching exercises for majormuscle groups |
6RM tests | Leg press, Leg curl, Leg extension Agility training for two weeks | 1 month break during summertime | ||
7–8 | Period 4 | Warm-up with balance exercises; Hypertrophy: Resistance training at 70% 1RM, 3 × 10 reps (resistance is increased by 1–2 kg if predefined number of reps is exceeded) | Warm-up (as in periods 3–4) 20-min continuous walk with RPE 13 | Strength exercises for lower limb muscles with green/blue Thera Band CLX; Postural balance exercise; Stretching exercises for major muscle groups |
9–10 | Period 5 | Warm-up with balance exercises; Hypertrophy: Resistance 80%, 1–2 × 10 reps (resistance is increased by 1–2 kg if predefined number of reps is exceeded) Power: Resistance 60%, 1–2 × 6–8 (fast contractions) | Warm-up (as in periods 3–4); 20-min continuous walk with RPE 13 or 20-min walk with < 1 min intervals with RPE 15 | Strength exercises for lower limb muscles with blue TheraBand CLX;Postural balance exercise; Stretching exercises for major muscle groups |
6RM tests | Leg press, Leg curl, Leg extension | |||
11–12 | Period 6 | Warm-up with balance exercises; Power: Resistance 60%, 3 × 6 reps (fast contractions) Hypertrophy: Resistance 80%, 2 × 10 reps (resistance is increased by 1–2 kg if predefined number of reps is exceeded) | Warm-up (as in periods 3–4); 20-min walk with < 1 min intervals with RPE 15 | Strength exercises for lower limb muscles with blue TheraBand CLX; Postural balance exercise; Stretching exercises for major muscle groups |
Cognitive computer-based training (CT)
Participant safety and data quality assurance
Statistical analysis and sample size
Current status
Discussion
Acknowledgements
Funding
Availability of data and materials
Date and version identifier
-
The recruitment end date was changed from 01/03/2018 to 01/04/2018.
-
The overall trial end date was changed from 31/12/2018 to 01/04/2019.
-
The recruitment end date was changed from 31/12/2017 to 01/03/2018.
-
The following measurements were added:1.Isometric knee extension and grip strength are measured at baseline and 12 months.2.Lower body extension power is measured using the Nottingham power rig at baseline and 12 months.3.Level of sedentary behavior is assessed through self-reporting and use of an accelerometer at baseline, 6 and 12 months.4.ADL and IADL are measured with a standardized questionnaire at baseline, 6 and 12 months.5.Emotional well-being is measured with the satisfaction with life scale, Diener 1989; Internationally reliable short form of the Positive and Negative Affect Schedule at baseline, 6 and 12 months, and personality is assessed with the Eysenck Personality Inventory, Floderus B. 1974, at baseline and 12 months and the NEO-Personality Inventory-3 (NEO-PI) at 12 months.